Generic name · Chemotherapy / PD-L1 Biologic
Atezolizumab J-Code / HCPCS Code
In short
Atezolizumab is billed under HCPCS J9022 — Injection, atezolizumab, 10 mg. One billing unit is 10 mg.
Reference
- Code
- J9022 — Injection, atezolizumab, 10 mgMed-Code curated
- Billing unit
- 10 mg
- Same code in the directory
- Tecentriq
- Pharmacologic class
- Programmed Death Receptor-1 Blocking Antibody; EndoglycosidaseFrom the FDA listings below
- Labelers
- Genentech, Inc.
- J-code category
- Chemotherapy / PD-L1 Biologic
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tecentriqatezolizumab | Atezolizumab 1200 mg/20mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-917 |
| Tecentriqatezolizumab | Atezolizumab 840 mg/14mL | Injection, SolutionIntravenous | Genentech, Inc. | 50242-918 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Tecentriq Hybrezaatezolizumab and hyaluronidase-tqjs | Atezolizumab 1875 mg/15mL; Hyaluronidase (Human recombinant) 30000 U/15mL | InjectionSubcutaneous | Genentech, Inc. | 50242-933 |
NDCs billed under J9022
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 2 NDCs to J9022 for Tecentriq. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Tecentriq | 50242-0917-01 | Genentech, Inc. | 20 | 120 |
| Tecentriq | 50242-0918-01 | Genentech, Inc. | 14 | 84 |